These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18287885)

  • 1. Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties.
    Graversen JH; Laurberg JM; Andersen MH; Falk E; Nieland J; Christensen J; Etzerodt M; Thøgersen HC; Moestrup SK
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):170-7. PubMed ID: 18287885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia.
    Belalcazar LM; Merched A; Carr B; Oka K; Chen KH; Pastore L; Beaudet A; Chan L
    Circulation; 2003 Jun; 107(21):2726-32. PubMed ID: 12742997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
    Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
    J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice.
    Chroni A; Kan HY; Shkodrani A; Liu T; Zannis VI
    Biochemistry; 2005 Mar; 44(10):4108-17. PubMed ID: 15751988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor.
    Moore RE; Kawashiri MA; Kitajima K; Secreto A; Millar JS; Pratico D; Rader DJ
    Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1914-20. PubMed ID: 12933536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased protein nitration burden in the atherosclerotic lesions and plasma of apolipoprotein A-I deficient mice.
    Parastatidis I; Thomson L; Fries DM; Moore RE; Tohyama J; Fu X; Hazen SL; Heijnen HF; Dennehy MK; Liebler DC; Rader DJ; Ischiropoulos H
    Circ Res; 2007 Aug; 101(4):368-76. PubMed ID: 17615369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in apolipoprotein A- I and it's anti-atherosclerosis properties].
    Li M; Liu ZM
    Sheng Wu Gong Cheng Xue Bao; 2003 Jul; 19(4):387-91. PubMed ID: 15969051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency.
    Vaessen SF; Veldman RJ; Comijn EM; Snapper J; Sierts JA; van den Oever K; Beattie SG; Twisk J; Kuivenhoven JA
    J Gene Med; 2009 Aug; 11(8):697-707. PubMed ID: 19431216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
    Sherman CB; Peterson SJ; Frishman WH
    Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice.
    Pedersen TX; Bro S; Andersen MH; Etzerodt M; Jauhiainen M; Moestrup S; Nielsen LB
    Atherosclerosis; 2009 Feb; 202(2):372-81. PubMed ID: 18489910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Caucasian male with very low blood cholesterol and low apoA-II without evidence of atherosclerosis.
    Park SH; Kim JR; Park JE; Cho KH
    Eur J Clin Invest; 2007 Apr; 37(4):249-56. PubMed ID: 17373959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization.
    Shah PK; Yano J; Reyes O; Chyu KY; Kaul S; Bisgaier CL; Drake S; Cercek B
    Circulation; 2001 Jun; 103(25):3047-50. PubMed ID: 11425766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo.
    Zhang Y; Zanotti I; Reilly MP; Glick JM; Rothblat GH; Rader DJ
    Circulation; 2003 Aug; 108(6):661-3. PubMed ID: 12900335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
    Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D
    Eur J Pharmacol; 2007 Apr; 561(1-3):105-11. PubMed ID: 17306791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haptoglobin binding to apolipoprotein A-I prevents damage from hydroxyl radicals on its stimulatory activity of the enzyme lecithin-cholesterol acyl-transferase.
    Salvatore A; Cigliano L; Bucci EM; Corpillo D; Velasco S; Carlucci A; Pedone C; Abrescia P
    Biochemistry; 2007 Oct; 46(39):11158-68. PubMed ID: 17824618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis.
    Moerland M; Samyn H; van Gent T; van Haperen R; Dallinga-Thie G; Grosveld F; van Tol A; de Crom R
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1277-82. PubMed ID: 18421000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase 8 degrades apolipoprotein A-I and reduces its cholesterol efflux capacity.
    Salminen A; Åström P; Metso J; Soliymani R; Salo T; Jauhiainen M; Pussinen PJ; Sorsa T
    FASEB J; 2015 Apr; 29(4):1435-45. PubMed ID: 25550459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report.
    Ditiatkovski M; Palsson J; Chin-Dusting J; Remaley AT; Sviridov D
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1301-1306. PubMed ID: 28522696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARgamma1-induced caveolin-1 enhances cholesterol efflux and attenuates atherosclerosis in apolipoprotein E-deficient mice.
    Hu Q; Zhang XJ; Liu CX; Wang XP; Zhang Y
    J Vasc Res; 2010; 47(1):69-79. PubMed ID: 19729954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice.
    Zhao Y; Su B; Jacobs RL; Kennedy B; Francis GA; Waddington E; Brosnan JT; Vance JE; Vance DE
    Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1349-55. PubMed ID: 19520976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.